Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Donat

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Diabetes Care|July 27, 2005
Transfer of glyburide and glipizide into breast milkDenice S Feig, Gerald G Briggs, Jennifer M Kraemer, et al.
Histopathology|February 6, 2013
Chromosomal and genetic changes produced in tumoral progression of embryonal rhabdomyosarcomaR Gil-Benso, T San-Miguel, R C Callaghan, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 5, 2016
Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?A Di Cataldo, A Agodi, J Balaguer, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Diabetes Care|July 27, 2005
Transfer of glyburide and glipizide into breast milkDenice S Feig, Gerald G Briggs, Jennifer M Kraemer, et al.
Histopathology|February 6, 2013
Chromosomal and genetic changes produced in tumoral progression of embryonal rhabdomyosarcomaR Gil-Benso, T San-Miguel, R C Callaghan, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 5, 2016
Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?A Di Cataldo, A Agodi, J Balaguer, et al.
Pageof 4